Global AL Amyloidosis Market to Reach $6.37B by 2030 at 12.6% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The AL Amyloidosis Market In 2026, And How Will Its Value Evolve By 2030?

The al amyloidosis market has experienced rapid expansion in recent times. This market is predicted to increase from $3.51 billion in 2025 to $3.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. Driving this past growth were factors including a scarcity of treatment options, a dependency on conventional chemotherapy, reduced disease awareness, insufficient organ-specific supportive care, and limited entry to specialized treatment centers.

The market for al amyloidosis is projected to experience swift expansion in the coming years. This market is anticipated to reach $6.38 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. Several factors are expected to drive this growth during the forecast period, including the creation of new targeted treatments, the wider use of monoclonal antibodies and proteasome inhibitors, the broadening of stem cell transplant initiatives, enhanced healthcare infrastructure for rare conditions, and more sophisticated diagnostic tools for prompt identification. Key trends for this period encompass the growing uptake of targeted therapies for al amyloidosis, increased application of monoclonal antibodies and proteasome inhibitors, the extension of stem cell transplant operations, a heightened emphasis on organ-specific supportive care, and greater public awareness leading to earlier diagnosis of al amyloidosis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

Which Factors Are Influencing The Growth Of The AL Amyloidosis Market?

The increasing occurrence of plasma cell disorders is anticipated to fuel the expansion of the AL amyloidosis market in the future. These disorders involve abnormal plasma cells generating an abundance of unusual antibodies, which can lead to organ harm. This surge in plasma cell disorder cases is linked to an aging global population, longer lifespans, and improved diagnostic methods. AL amyloidosis itself stems from plasma cell disorders, particularly the excessive production of abnormal light chain proteins. This can result in amyloid deposits forming in various organs and tissues, intensifying the impact of plasma cell dyscrasias. An example illustrates this trend: reports from The American Cancer Society (ACS), a US-based nonprofit, indicated in August 2024 that approximately 35,780 new multiple myeloma cases are projected for diagnosis in 2024 (comprising 19,520 men and 16,260 women). Additionally, around 12,540 deaths are anticipated, with 7,020 occurring in men and 5,520 in women. Consequently, the increasing prevalence of plasma cell disorders is a significant factor propelling the expansion of the AL amyloidosis market.

How Is The AL Amyloidosis Market Categorized Across Its Segment Groups?

The al amyloidosis market covered in this report is segmented –

1) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy

2) By Drugs: Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs

3) By Route Of Administration: Intravenous, Oral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy

2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)

3) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant

4) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors

Which Trends Are Influencing Demand In The AL Amyloidosis Market?

Leading companies in the AL amyloidosis market are prioritizing the creation of innovative treatments, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, to enhance therapeutic effectiveness and patient outcomes. This advanced form of immunotherapy, next-generation BCMA-directed CAR T-cell therapy, involves modifying a patient’s T cells to specifically target and eliminate BCMA on the surface of cancer cells, particularly in multiple myeloma. For example, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for NXC-201, intended for the treatment of the severe blood condition, Amyloid Light Chain (AL) Amyloidosis. NXC-201 is a next-generation CAR-T cell therapy currently undergoing clinical trials for amyloid light chain (AL) amyloidosis, exhibiting encouraging results such as a 100% hematologic response rate and improvements in organ health for patients who had previously failed other therapies.

Which Firms Are Influencing Competition In The AL Amyloidosis Market?

Major companies operating in the al amyloidosis market are Johnson & Johnson, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Novartis AG, Merck & Co. Inc., Eli Lilly and Company, GlaxoSmithKline plc, Genmab A/S, Prothena Corporation plc, BridgeBio Pharma Inc., Oncopeptides AB, Ionis Pharmaceuticals Inc., Neurimmune AG, Immix Biopharma Inc., Attralus Inc.

Get The Full AL Amyloidosis Market Report:

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

Where Is The AL Amyloidosis Market Primarily Concentrated By Region?

North America was the largest region in the AL amyloidosis market in 2025. The regions covered in the al amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized AL Amyloidosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

Browse Through More Reports Similar to the Global AL Amyloidosis Market 2026, By The Business Research Company

Keloids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795